Price Alert

Taysha Gene Therapies Inc... (TSHA)

NASDAQ: TSHA · Real-Time Price · USD

2.94

0.00 (0.00%)

At close: Aug 18, 2025, 3:59 PM

2.96

0.85%

After-hours: Aug 18, 2025, 06:24 PM EDT

0.00% (1D)

Bid	2.86
Market Cap	696.93M
Revenue (ttm)	7.22M
Net Income (ttm)	-86.77M
EPS (ttm)	-0.34
PE Ratio (ttm)	-8.63
Forward PE	-7.37
Analyst	Buy

Ask	2.98
Volume	2,296,472
Avg. Volume (20D)	3,546,891
Open	2.95
Previous Close	2.94
Day's Range	2.88 - 3.04
52-Week Range	1.05 - 3.31
Beta	0.96

About TSHA

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol TSHA

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for TSHA stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Earnings Surprise

Taysha Gene Therapies has released their quartely earnings on Aug 12, 2025:

Revenue of $1.99M exceeds estimates by $335.05K, with 78.60% YoY growth.

EPS of -0.09 misses estimates by -0.02, with 0.00% YoY growth.

Next Earnings Release

Taysha Gene Therapies Inc. is scheduled to release its earnings on Nov 12, 2025, during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

2 months ago

+12.7%

Taysha Gene Therapies shares are trading higher af... Unlock content with Pro Subscription

2 months ago

-6.51%

Taysha Gene Therapies shares are trading higher. The company announced a proposed public offering of common stock.

News

6 days ago · zacks.com

Taysha Gene Therapies, Inc. (TSHA) Reports Q2 Loss, Beats Revenue Estimates

Taysha Gene Therapies, Inc. (TSHA) came out with a quarterly loss of $0.09 per share versus the Zacks Consensus Estimate of a loss of $0.07. This compares to a loss of $0.09 per share a year ago.

1 week ago · seekingalpha.com

Taysha Gene Therapies, Inc. (TSHA) Q2 2025 Earnings Call Transcript

Taysha Gene Therapies, Inc. (NASDAQ:TSHA ) Q2 2025 Earnings Conference Call August 12, 2025 8:30 AM ET Company Participants Hayleigh Collins - Director of Corporate Communications & Investor Relations...

2 weeks ago · zacks.com

Will Taysha Gene Therapies, Inc. (TSHA) Report Negative Q2 Earnings? What You Should Know

Taysha Gene Therapies (TSHA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 month ago · zacks.com

Taysha Gene Therapies (TSHA) Moves to Buy: Rationale Behind the Upgrade

Taysha Gene Therapies (TSHA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

2 months ago · seekingalpha.com

Taysha: TSHA-102 Presses On With IND Part B Protocol And SAP Amendments

Taysha Gene Therapies, Inc. achieved positive updated data from Part A of the phase 1/2 REVEAL study using TSHA-102 to treat patients with Rett Syndrome. Alignment gained with FDA on IND amendments to...

2 months ago · benzinga.com

Why Is Taysha Gene Therapies Stock Trading Higher On Thursday?

Taysha Gene Therapies Inc. TSHA on Wednesday announced details of its planned pivotal Part B trial design for TSHA-102 following written alignment from the U.S. Food and Drug Administration (FDA).